Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site
Howard Hughes Medical Institute, Program in Molecular Medicine; Department of Cancer Biology
3T3 Cells; Alanine; Animals; Cell Transformation, Neoplastic; Chick Embryo; Glutamates; Glutamic Acid; Kinetics; Mice; Mutation; *Oncogenes; Phosphorylation; Plasmids; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor, erbB-2; Serine
Life Sciences | Medicine and Health Sciences
The erbB oncogene encodes an altered form of the epidermal growth factor (EGF) receptor that lacks the extracellular ligand binding domain. This oncogene is exclusively leukemogenic. However, an increase in oncogenic potential and a broadening of the tissue specificity of tumor formation occurs after retroviral transduction of erbB. The increased oncogenic potential correlates with structural alterations within the erbB gene. One common event is the deletion of a serine phosphorylation site located within the COOH-terminal domain. This site of phosphorylation has been demonstrated to be required for EGF-induced desensitization of signaling by the EGF receptor (Countaway, J. L., Nairn, A. C., and Davis, R.J. (1992) J. Biol. Chem. 267, 1129-1140). Here we show that the mutation of erbB at this negative regulatory serine phosphorylation site causes fibroblast transformation in vitro and is associated with an increased oncogenic potential in vivo.
J Biol Chem. 1992 Apr 25;267(12):7967-70.
The Journal of biological chemistry
Theroux SJ, Taglienti CA, Nair N, Countaway JL, Robinson HL, Davis RJ. (1992). Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site. Open Access Articles. Retrieved from https://escholarship.umassmed.edu/oapubs/841